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The NKR-P1 receptors were identified as prototypical natural killer (NK) cell surface anti-
gens and later shown to be conserved from rodents to humans on NK cells and subsets of
T cells. C-type lectin-like in nature, they were originally shown to be capable of activating
NK cell function and to recognize ligands on tumor cells. However, certain family members
have subsequently been shown to be capable of inhibiting NK cell activity, and to recognize
proteins encoded by a family of genetically linked C-type lectin-related ligands. Some of
these ligands are expressed by normal, healthy cells, and modulated during transforma-
tion, infection, and cellular stress, while other ligands are upregulated during the immune
response and during pathological circumstances. Here, we discuss historical and recent
developments in NKR-P1 biology that demonstrate this NK receptor–ligand system to be
far more complex and diverse than originally anticipated.
Keywords: natural killer cell, innate immunity, C-type lectin-like, Nkrp1, CD161, Clr, Ocil, LLT1
INTRODUCTION
Natural killer (NK) cells are innate lymphocytes that recognize
and respond to a variety of different pathological target cells
via cytotoxicity and secretion of type I helper cytokines, most
notably IFN-γ. However, they can also secrete TNF-α, GM-CSF,
and chemokines, to initiate crosstalk with the adaptive immune
system. Target cell recognition is mediated by a variety of recep-
tors on NK cells that detect specific cognate ligands, which in
turn are differentially expressed on pathological versus normal
cells (1). Healthy cells broadly express a number of inhibitory
ligands (including MHC-I molecules), which are frequently lost
during pathological transformation, infection, or cell stress; this
has been termed “missing-self” recognition (1, 2). On the other
hand, most stimulatory ligands are minimally expressed by healthy
cells, but are strongly upregulated during cellular pathologies; this
phenomenon has been termed “induced-self” recognition (3).
Typically, both missing-self and induced-self recognition events
operate simultaneously to shift the balance from NK cell tolerance
to induction of NK cell activation, via an integration of target cell
recognition signals (3, 4).
Many NK cell receptors are encoded by genes linked to the NK
gene complex (NKC), located on chromosome 6 in mice, chromo-
some 4 in rats, and chromosome 12 in humans (5–7) (Figure 1).
The NKC is also conserved among several other species, including
dogs (7), cattle (where it is split between two chromosomes) (7),
and chickens (where it is genetically linked to the MHC region) (8).
However, a number of NK cell receptor gene families are linked to
the leukocyte receptor cluster (LRC), located on mouse chromo-
some 7, rat chromosome 1, and human chromosome 19 (9–12).
There are also numerous other NK cell receptors encoded in var-
ious regions in the genome, including the SAP/SLAM family of
receptors found on mouse and human chromosome 1 (13, 14), the
natural cytotoxicity receptors (NCR1, 2, 3) (15, 16), and others.
Within these regions, most NK cell receptors can be broadly classi-
fied into two structurally divergent categories: immunoglobulin-
like receptors (e.g., KIR, NCR) and C-type lectin-like receptors
(e.g., KLR, Ly49).
Among the earliest identified group of NK cell receptors is
the NKR-P1 family (encoded by the Klrb1 genes; centromeric
to Cd69 in the NKC) [Reviewed in Ref. (17)] (Figure 1). This
family of receptors is somewhat unique within the NKC, because
their ligands are other C-type lectin-related proteins (Clr; encoded
by the Clec2 genes), and the Clr/Clec2 loci are genetically inter-
spersed amongst the Nkrp1/Klrb1 receptor genes themselves (18–
20) (Figure 1). Although a number of functional interactions have
been demonstrated to date between different NKR-P1 receptors
and Clr ligands in mice (21), rats (22), and humans (23), many
of the receptor–ligand interactions remain unknown, and most
have unknown function. This review will outline the historical and
recent discoveries surrounding the NKR-P1:Clr systems in rodents
and humans, and provide an update on their nomenclature, as well
as known expression, structure, and function.
HISTORICAL PERSPECTIVE
DISCOVERY OF THE NKR-P1 (Klrb1/CD161/Ly-55/Ly-59/Clec5b)
RECEPTORS
The first receptor identified to be selectively expressed by NK
cells was the mouse NK1 alloantigen, which was discovered by
Glimcher et al. in 1977 and found to be differentially expressed
across mouse strains (24) [reviewed in Ref. (17)]. The develop-
ment of a specific monoclonal antibody (PK136 mAb) facilitated
its designation as the NK1.1 antigen, permitting the detection and
purification of NK cells in select inbred mouse strains (25, 26).
Subsequently, the NK1.1 antigen was shown to possess activating
function (27, 28), providing direct evidence that NK cells express
receptors that may be capable of recognizing cognate ligands on
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FIGURE 1 | Updated map of the NKC on mouse chromosome 6,
highlighting the Nkrp1/Klrb1 and Clr/Clec2 receptor–ligand system.
The mouse Nkrp1 receptor genes (official gene nomenclature, Klrb1) are
highlighted at the top, with the Clr ligand genes (official gene
nomenclature, Clec2) denoted below, located between the A2m and Cd69
genes (17). The triangles depict the gene orientation (plus or minus strand)
and their color signifies the known or suspected function of the gene
products in regulating NK cell activity, as follows: co-stimulatory (green);
co-inhibitory (red); bifunctional (green/red); pseudogene (ps, blue); or
unknown (purple). Other select NK receptor genes located telomeric to
Cd69 are also depicted with common and official (Klr ) gene
nomenclatures. Not to scale.
target cells (29). However, the identity of the NK1.1 antigen would
remain unknown for several years (30).
In 1989, Chambers et al. generated a mAb (3.2.3) against a cell
surface antigen present at high density on rat NK cells and purified
rat lymphokine-activated killer (LAK) cells (31). The 3.2.3 anti-
body was shown to induce redirected NK cell cytotoxicity against
FcR+ targets, as well as exocytosis of NK cell cytolytic granules,
classifying it as an activating receptor. They called the antigen
NKR-P1A (32). Since ligation of mouse NK1.1 and rat NKR-P1A
both induced NK cell-mediated cytotoxicity, the hypothesis arose
that they could represent homologous structures (28).
Consequently, Giorda et al. screened a B6-strain mouse LAK
cDNA library using the rat NKR-P1A cDNA, and identified three
mouse NKR-P1 homologs, which they called NKR-P1A (clone 2),
NKR-P1B (clone 34), and NKR-P1C (clone 40) (33). The cloned
sequences corresponding to the mouse NKR-P1 cDNA were found
to exist in different sizes, suggestive of alternative splicing. Over-
all, these cDNA shared between 61–87% identity at the amino
acid level with rat NKR-P1A, with high similarity existing in the
extracellular lectin-like region, including several C residues and
N -linked glycosylation sites. The discovery and designation of the
NKC in mice in 1991 showed that the NKR-P1 receptor loci were
distinct from the Ly49 receptor loci, despite their common expres-
sion and structural similarity (34). Importantly, however, their
genetic linkage demonstrated that a specific location on mouse
chromosome 6 was dedicated to NK cell function (5). With the
physical mapping of the NKR-P1 genes and the locus encoding the
NK1.1 antigen to the same region of mouse chromosome 6, along
with their similar expression, structure, and function, it became
increasingly likely that the NK1.1 antigen belonged to the NKR-P1
family, and this was formally demonstrated by Ryan et al. in 1992,
via expression cloning of the mouse Nkrp1cB6 cDNA using PK136
mAb (35).
However, it later became clear that the strain-dependent expres-
sion of the NK1.1 antigen was not only due to allelic expression
of the Nkrp1cB6 gene product. In 1999, two groups demonstrated
that Nkrp1b gene products from the Swiss-NIH and SJL strains
also reacted with the NK1.1 mAb, PK136 (36, 37). Furthermore,
the NKR-P1BSw/SJL receptors inhibited NK cell function rather
than activating NK cells like NKR-P1C. In these studies, the cloned
NKR-P1BB6 (NKR-P1D) gene products did not react with NK1.1
mAb, nor did the NKR-P1CSw/SJL gene products, making it unclear
whether they were alleles of existing genetic loci or new genes. In
any case, these results demonstrated that polymorphisms exist at
both the mouse Nkrp1b and Nkrp1c loci (see below).
In 2001, a BAC contig of the Nkrp1 gene cluster in the B6
mouse strain allowed for the identification of several new genomic
sequences, including Nkrp1d (Nkrp1bB6), Nkrp1e, and Nkrp1f
(38). The Nkrp1d sequence is 90% similar to that of Nkrp1b, and
likely represents an allele of the Nkrp1b locus, rather than a new
gene, since the coding sequence resembles that of the cloned NKR-
P1BB6 cDNA reported above (see also below) (37, 39). Nkrp1e
contains an early stop codon in exon-3, and splicing of intron-5 is
predicted to create a frame-shift in the open reading frame (ORF),
suggesting it may represent a pseudogene, at least in the B6-strain
(38). The Nkrp1f gene appears to be intact and is predicted to code
for a functional protein. Work in our lab has identified the latest
mouse family member, Nkrp1g (21, 39) (Figure 1).
Subsequent investigation into the nature of strain-dependent
NK1.1 reactivity showed that it was due, at least in part, to a sin-
gle amino acid substitution in the NKR-P1B gene products (and
presumably the NKR-P1C gene products, although this remains
to be shown) (39). The more recent development of NKR-P1BB6
(NKR-P1D) mAb (18, 40) has shown that, unlike NKR-P1C, which
is expressed uniformly by all NK cells in B6 mice, NKR-P1B is var-
iegated and only expressed at high levels on a subset of mature
NK cells (36, 37, 41). Previous Southern blot analyses and more
recent aCGH analyses, paired with phenotypic NK subset com-
parisons, have shown this trend to be a generalized phenomenon
across many strains (34, 42).
A recent comprehensive study by Hao et al. provided an in-
depth computational analysis of the NKC regions from many
species, including the rat Nkrp1 genes (7). The rat NKC has at
least four Nkrp1 genes, predicted to represent orthologs of the
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Nkrp1a/c, Nkrp1b/d, Nkrp1f, and Nkrp1g gene sets (Figure 2).
Like Nkrp1bB6, the rat Nkrp1c gene likely represents a divergent
Nkrp1b allele present in the PVG rat strain (Nkrp1bPVG; see below)
(43). While the activating function of the rat NKR-P1A receptor
was known since the late 1980s, the inhibitory function of the
rat NKR-P1B isoform was not shown until much later. Here, the
Miller lab transfected human YTS cells with a rat cDNA library
and sorted cells using the 10/78 mAb (similar NKR-P1A reactivity
to 3.2.3 mAb) (44). Sequence analysis of positive clones fell into
two groups corresponding to either rat NKR-P1A or NKR-P1B.
Using chromium release assays, they showed that the rat NKR-
P1B clones inhibited NK cytotoxicity. It is now clear that both
the NKR-P1A/B gene products from some rat strains react with
the 10/78 and 3.2.3 mAb, demonstrating that polymorphisms also
exist in selected rat Nkrp1 loci (45).
The closest human homolog, NKR-P1A (CD161/KLRB1), was
identified in 1994 through the development of the DX1 mAb
against human LAK cells (46). Human NKR-P1A shares 46%
homology at the amino acid level with rat NKR-P1A and 46–
47% homology with the mouse NKR-P1 proteins, but significantly
lower homology with other C-type lectin-like NK cell receptors.
Ligation of human NKR-P1A with DX1 mAb did not induce cyto-
toxicity against FcR-bearing P815 cells or have an effect on lysis
of K562 target cells. However, when added to NK clones with the
spontaneous ability to lyse P815 cells, cytotoxicity was inhibited,
while F(ab′)2 of anti-NKR-P1A mAb did not inhibit, suggesting
FcR cross-linking was important. Paradoxically, NK cell clones
that did not spontaneously kill P815 targets could have a small
proportion induced to kill P815 in the presence of NKR-P1A mAb.
In 2005, two groups showed that the NKR-P1A receptor was indeed
inhibitory on human NK cells, demonstrating it to be a likely func-
tional homolog of the mouse and rat NKR-P1B receptors (47, 48).
Also similar to the rodent NKR-P1B, only a subset of human NK
cells express NKR-P1A (46). However, the existence of another
putative inhibitory receptor in rodents, NKR-P1G, calls into ques-
tion orthology of human NKR-P1A with rodent NKR-P1B (7).
Whereas several different NKR-P1 transcripts could be detected
by Northern blot in mouse NK cells (33, 49), only one band was
detected in human NK cells (46). Nonetheless, an apparent lack of
stimulatory NKR-P1 homologs in the human genome was recently
re-investigated by the Steinle group, who suggested that the human
KLRF1/2 gene products, located telomeric to CD69, may actually
represent divergent activating NKR-P1 homologs (see below) (23)
(Figure 2).
DISCOVERY OF THE Clr (Clec2d/Ocil/LLT1) LIGANDS
While investigating bone morphogenesis, Zhou et al. discovered
a gene product they designated osteoclast inhibitory lectin (Ocil),
after its ability to inhibit osteoclast formation when expressed on
osteoblast cells (50). They went on to show that Ocil was a proto-
typical member of a group of similar gene products in mice (Ocil,
Ocilrp1, Ocilrp2) (51). The extracellular domains of all three gene
products are similar to each other at the amino acid (>70%) and
nucleotide (~90%) levels. Around the same time, Plougastel et al.
identified a novel set of Clr genes by sequencing B6-strain BACs of
the NKC region centromeric to Cd69 (52). The Clr gene products
FIGURE 2 | Updated high-resolution maps of the rodent and human
Nkrp1/KLRB/F and Clr/CLEC2 receptor–ligand systems. (Top) The mouse
Nkrp1/Klrb1 receptor genes and Clr/Clec2 ligand genes on mouse
chromosome 6 (B6-strain reference sequence, genome build: December
2011, GRCm38/mm10) are depicted, along with their orientation (triangle
direction), known or suspected function (triangle color), and intron–exon
structure (vertical exon lines); triangle representations are as in Figure 1.
(Middle) The rat Nkrp1/Klrb1 receptor genes and Clr/Clec2 ligand genes on rat
chromosome 4 (BN-strain reference sequence, genome build: November
2004, Baylor 3.4/rn4) are depicted as above. (Bottom) The human KLRB/F
receptor genes and CLEC ligand genes on human chromosome 12 (genome
build: February 2009, GRCh37/hg19) are depicted as above. Not to scale.
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were shown to possess 40% amino acid identity to the lectin-like
domain of CD69, and 80–90% homology at the nucleotide level to
each other. They named the genes Clr-a, -b, -c, -d, -e, -f, -g, where
Clr-b was identical to Ocil, Clr-g was identical to a splice variant of
Ocilrp2, and Clr-d (and perhaps Clr-c) were similar to splice vari-
ants of Ocilrp1 (51, 52). Since then, new family members, namely
Clr-h, Clr-i, and Clr-j, were discovered by hybridizing partial Clr
PCR products to mouse BALB/c and 129-strain BACs (21, 39)
(Figure 1). While the majority of the Clr genes are predicted to
code for functional proteins, Clr-e likely represents a pseudogene,
due to a frame-shift (52, 53); Clr-i is a predicted pseudogene, due
to multiple stop codons in all reading frames (21, 53); and Clr-j
is only a gene fragment (53). Unfortunately, several nomenclature
issues complicate the Clr literature, including synonyms and the
existence of splice isoforms (see below) (Figure 1).
Subsequent to the identification of the Ocil/Clr gene family,
several screens aimed at identifying NKR-P1 ligands demonstrated
interactions between gene products of the two families [reviewed
in Ref. (17)]. Briefly, interactions between the NKR-P1B/D:Clr-
b as well as NKR-P1F:Clr-g receptor–ligand pairs were shown
using cellular assays (involving BWZ.36 reporter cells bearing
CD3ζ/NKR-P1 fusion receptors), NKR-P1 tetramers, and block-
ing mAbs for NKR-P1BB6 (a.k.a., NKR-P1D; 2D12 mAb) or Clr-b
(4A6 mAb) (18, 20). These results were significant in that they
showed an interaction between the NKR-P1 receptors, which were
previously thought to recognize oligosaccharides (54, 55), and pro-
tein ligands. Thus, the NKR-P1 receptors are notable in that they
recognize other Clr proteins encoded by the Ocil/Clr/Clec2 ligand
genes linked to the Nkrp1/Klrb1 receptor genes. More recently,
additional interactions have been shown in the mouse system,
including strain-dependent conservation of NKR-P1B/D:Clr-b,
NKR-P1F:Clr-c, -d, -g, and NKR-P1G:Clr-d, -f, -g (21) (Figure 1).
The first ligand identified in the rat system was a viral
immunoevasin, RCTL, a spliced ORF with C-type lectin-like
sequence homology identified in 2001 (56), derived from the
rat cytomegalovirus-English isolate [RCMV-E; Mhv8 (57)]. rctl is
expressed as an early gene upon infection of rat embryonic fibrob-
last (REF) cells (45, 56). The RCTL gene product appears to func-
tionally replace the endogenous Clr-b-like ligand (rat Clec2d11),
which is rapidly lost during RCMV-E infection; notably, both
the host and viral ligands are recognized by specific allele(s) of
the NKR-P1B receptor in certain rat strains (45). Prior to this
work, no information was available regarding the rat Ocil/Clr
gene family, until a breakthrough publication in 2006 by Hao
et al. described the complete repertoire of NKC-associated Clec-
like genes in several species (7). This in-depth analysis outlined
at least 11 rat Clec2d-like genes or pseudogenes, making the rat
system the most complex family identified to date. Due to close
sequence homology and an inability to determine strict orthology
with the mouse family members, the rat Clr genes were simply
designated Clec2d1-11 (centromeric to telomeric), with a close rel-
ative of mouse Clr-b (mouse Clec2d8) predicted to be rat Clec2d11,
based upon sequence, structure, and genomic position (7). Indeed,
rat Clec2d11 was shown to be recognized by two distinct host
NKR-P1B alleles (45). In 2009, the promoter region of a rat Ocil
homolog was first described (58); however, the gene annotated rat
Ocil is another Clr family member, rat Clec2d5 (7).
The first in-depth analysis of rat NKR-P1 ligands, which
adopted a rat Clr-1–11 nomenclature based upon the correspond-
ing Clec2d1–11 assignments, used an NFAT-driven GFP-reporter
cell assay (BWN3G, similar to the BWZ.36 LacZ -reporter cell
assay), to show that rat NKR-P1A and NKR-P1B (cluster 1 recep-
tors) recognize Clr-11, while NKR-P1F and NKR-P1G (cluster 2
receptors) recognize an overlapping set of ligands, namely Clr-2,
-3, -4, -6, -7 and Clr-2, -6, -7, respectively (59) (Figure 2). Follow-
up work by this group showed that the mouse and rat NKR-P1F/G
receptors are highly xenoreactive, cross-recognizing correspond-
ing ligands from the other species and allowing some degree of
assignment of functional orthology (22).
In the human system, a Clr sequence was discovered in the
NKC in 1999 by Boles et al. by searching the EST database with
a consensus sequence of known human C-type lectin-like recep-
tors (60). They screened an NK cell cDNA library and identified an
850-bp cDNA, designated lectin-like transcript-1 (LLT1), and later
generated a mouse anti-LLT1 mAb (L9.7) by immunizing AKR/J2
mice with LLT1 fusion proteins (61). LLT1 is similar in struc-
ture and function to the mouse Clr gene products, and indeed
has been given the synonymous gene designation, CLEC2D, as the
mouse Clr-b locus (Clec2d). Actually, Hao et al. identified two
homologs, CLEC2D1p (a predicted pseudogene) and CLEC2D2
(which encodes LLT1) (7) (Figure 2). However, LLT1 also shares
significant homology with other rodent Clr gene products, as well
as other human gene products, such as KACL (CLEC2A), AICL
(CLEC2B), and CD69 (CLEC2C) (17, 23, 60, 62, 63). As with
mouse Ocil/Clr-b, human OCIL was also discovered separately
from LLT1 in 2004 (64), but the cDNA encodes an identical protein
to LLT1; human LLT1/OCIL is 42% identical to mouse Ocil/Clr-b
at the protein level.
The above features of LLT1 made it an attractive candi-
date for interaction with the human NKR-P1A receptor (61).
Indeed, in 2005, simultaneous publications from two groups for-
mally demonstrated an interaction between the human NKR-P1A
(KLRB1) receptor and the LLT1 (CLEC2D) ligand, using LLT1
multimers and liposomes, reciprocal NKR-P1A/LLT1 reporter cell
assays, as well as functional cytotoxicity and IFN-γ production
assays (47, 48). More recent studies have identified several splice
variants of the human CLEC2D gene, only one of which (LLT1)
appears to functionally bind the human NKR-P1A receptor (65)
(Oscar Aguilar; see GenBank KF958454-9, KF971856-9). As men-
tioned above, the Steinle lab has also reported significant CLEC2
group homology between KACL (CLEC2A, linked to its receptor,
KLRF2), AICL (CLEC2B, linked to its receptor, KLRF1), CD69
(CLEC2C, unknown receptor; between CLEC2D and CLEC2A/B),
and LLT1 (CLEC2D, linked to its receptor, KLRB1) (23) (Figure 2).
NOMENCLATURE ISSUES AND FUNCTIONAL HOMOLOGY
The NKR-P1:Clr receptor–ligand system has historically suffered
from considerable nomenclature issues, across different species as
well as among distinct strains within a given species. In the mouse
system, the receptors have been variably known as NK1/NK1.1 (an
alloantigen between mouse strains), Ly-55(a–c)/Ly-59 (lympho-
cyte antigens), NKR-P1 (A–G, the common names), Cd161 (after
the human receptor designation), Klrb1 (the official gene nomen-
clature, with members a–g ), and Clec5b (according to the C-type
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lectin-like nomenclature). While the official gene nomenclature
could have been designated killer-cell lectin-like receptor group-B,
with numerical family numbers (i.e., Klrb1-7 ; following the similar
Klra1-n designations for Ly49a–x), it has instead adopted a hybrid
lettered gene nomenclature, Klrb1a–g, after their common names.
Thus, NKR-P1A is encoded by Klrb1a, etc. However, this is com-
plicated by the fact that NKR-P1B and NKR-P1D are likely highly
divergent alleles of the same or a similarly evolved single genetic
locus; thus, NKR-P1B is encoded by Klrb1b, which is also known
as Klrb1d in the B6 mouse strain (i.e., NKR-P1BB6 is synonymous
with NKR-P1D). Following this, the remaining family members
are NKR-P1C (encoded by Klrb1c), NKR-P1F (Klrb1f), and NKR-
P1G (Klrb1g ), plus one predicted pseudogene, NKR-P1E (Klrb1e
or Klrb1-ps1) (53). While NKR-P1CB6 (Klrb1cB6) is widely thought
to represent “the” NK1.1 antigen, it is actually only crossreactive as
“one” NK1.1 antigen in the B6 and related mouse strains, as NKR-
P1B alleles from several strains (e.g., NKR-P1BSw/SJL) also encode
NK1.1 antigens, and the NK1.1 mAb was originally derived by
immunization of (C3H×BALB)F1 mice with CE-strain spleno-
cytes and bone marrow (BM) cells (not B6 cells) (26). In addition,
the Nkrp1g gene has also been referred to as a second Nkrp1e-like
sequence (Nkrp1e2) (17), and most recently just Klrb1, perhaps sig-
nifying the closest predicted human KLRB1 ortholog or functional
homolog.
Furthering this complexity, as with any gene family, the dis-
covery of the Ocil/Clr gene products by multiple groups has
complicated the ligand nomenclature, which has been officially
designated the Clec2 gene family. Thus, the known mouse Clr
ligands include Clr-a (encoded by Clec2e), Clr-b (Clec2d), Clr-c
(Clec2f), Clr-d (Clec2g ), Clr-f (Clec2h), and Clr-g (Clec2i). There
are also a number of predicted pseudogenes, including Clr-e
(Clec2-ps1; Clec2d5), three recently discovered members, Clr-h
(Clec2j), Clr-i (Clec2k/Clec2-ps2), Clr-j (Clec2-ps3) (53), and an
unlinked, more distantly related family member recently anno-
tated Bacl (Clec2l), although Bacl is not encoded in the NKC
(66). However, as mentioned above, under alternative nomen-
clature, other names have been assigned historically to the gene
products: Clr-a (Clec2e, Clec2d7), Clr-b (Clec2d, Ocil, Clec2d8),
Clr-c (Clec2f, Clr-z, Clec2d6), Clr-d (Clec2g, Ocilrp1, Ddv10, Clr-
x, Clec2d4), Clr-e (Clec2-ps1, Clec2d5), Clr-f (Clec2h, Clec2d2),
Clr-g (Clec2i, Ocilrp2, Dcl1, LCL-1(a–d), Clec2d3), Clr-h (Clec2j;
Clec2d1), Clr-i (Clec2k, Clec2-ps2), and Clr-j (Clec2-ps3) (7, 53).
Note that there are no annotated Clec2a-c genes in the mouse
genome database, but these have been assigned to the human
KACL (CLEC2A), AICL (CLEC2B), and CD69 (CLEC2C) loci.
Also, note that an alternative myeloid receptor named Clec2 exists,
which is distinct from the Clec2 gene family and is encoded by the
Clec1b gene (67). To date, many of the Clr have unknown recep-
tors and most have unknown physiological function. However,
the known mouse receptor:ligand pairs to date include NKR-
P1B/D:Clr-b, NKR-P1F:Clr-c, -d, -g, and NKR-P1G:Clr-d, -f, -g
in the B6, 129, and BALB/c strains (18, 20–22, 40) (Figure 1).
Adding to this diversity, the rat NKC contains 4 Nkrp1/Klrb1
and 11 Clr/Clec2 genes (7), and has had its share of nomen-
clature issues. The rat NKR-P1 receptors are fairly straightfor-
ward, and have been classified into two distinct structural and
functional clusters, NKR-P1A/B (cluster 1), and NKR-P1F/G
(cluster 2) (59). However, as in the mouse system, a highly diver-
gent allele of the NKR-P1B receptor in the PVG strain (NKR-
P1BPVG) has been alternately referred to as NKR-P1C (43). In
addition, early references to NKR-P1F-like sequences were also
called Klrb1c/NKR-P1C (68), and NKR-P1G-like sequences were
also called Klrb1d/NKR-P1E. Notwithstanding this, the receptor
designations have largely been resolved in recent literature. As
above, human KLRB1 may be more closely related to rat Klrb1g
than Klrb1b (7), but this remains to be demonstrated.
Nonetheless, there are significant deviations in the ligand
nomenclature, and due to the complexity and homology of the
rat Clec2 family, gene annotations are still being worked out
in the genome browsers1, with many being given RGD or LOC
designations (e.g., RGD1564464/LOC500331 for Clec2d1/Clr1; see
below). To nucleate the gene family, Hao et al. presented the
earliest complete characterization of the rat Clr genes, and des-
ignated them numerically, centromere to telomere, as Clec2d1–
11 (7). There have been few updated attempts to rename these
genes according to the mouse nomenclature, or to fully deduce
speculated orthologies [if indeed possible (7, 69)], so they have
simply been referred to as Clr-1–11 (22, 43, 59). However, the
annotated rat Ocil gene is Clec2d5 (Clr-5), distinct from a likely
functional homolog of mouse Ocil/Clr-b, rat Clr-11 (Clec2d11),
which is also the demonstrated rat NKR-P1B ligand (22, 45, 59).
To confuse matters further, there is an annotated rat Clec2d-
like-1 sequence (abbreviated Clec2dl1; not Clec2d11, or Clr-11)
that is actually rat Clec2d6, or Clr-6. Notwithstanding these dis-
crepancies, the known interactions in the rat system include:
NKR-P1A/B:Clr-11, NKR-P1F:Clr-2, -3, -4, -6, -7, and NKR-
P1G:Clr-2, -6, -7 in various rat strains (22, 45, 59). Interest-
ingly, the mouse and rat NKR-P1F/G proteins have been labeled
“promiscuous” because they share overlapping ligand specificity,
cross-react in a xenogeneic manner with their respective ligands,
and react with many rat tumor target cells (22). Indeed, the
mouse NKR-P1F/G receptors can respond equivalently or bet-
ter to their rat Clr ligand counterparts using functional reporter
assays (e.g., mouse NKR-P1G also weakly binds rat Clr-4) (22)
(Figure 2).
In humans, the system is relatively simple, apart from some syn-
onymous designations and recent developments. The lone human
NKR-P1A receptor (KLRB1/CD161/CLEC5B) possesses inhibitory
function upon binding to the closest Clr-related ligand, LLT1
(CLEC2D/OCIL/CLAX) (47, 48). This interaction is function-
ally similar to the rodent NKR-P1B:Clr-b interaction; however,
the receptor and ligand also share strong similarity with another
rodent (putative) inhibitory interaction, NKR-P1G:Clr-d, -f, -g.
Hao et al. originally identified two human Clec2d homologs, where
CLEC2D1p is a predicted pseudogene (a.k.a., LOC374443), and
CLEC2D2 encodes LLT1 (7). However, recent work has speculated
that the missing human functional equivalents of the rodent stim-
ulatory NKR-P1 receptors may actually be located telomeric to
CD69 (CLEC2C) as part of a greater KLRB/F family intermin-
gled amongst CLEC2 family ligands (7). Here, Nkp80 (KLRF1;
CLEC5C) and NKp65 (KLRF2) are genetically linked with their
1http://genome.ucsc.edu; http://www.ncbi.nlm.nih.gov
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respective ligands, AICL (CLEC2B) (62, 70) and KACL (CLEC2A)
(63, 71). Of note, CD69 (CLEC2C) itself and a newly characterized
non-NKC-encoded BACL (CLEC2L) have no known binding part-
ners, but notably the latter is genetically linked with another
lectin-like receptor, KLRG2 (CLEC15B) (66). There is also another
more distantly related gene encoding DCAL (CLECL1), located
between LLT1 (CLEC2D) and CD69 (CLEC2C) (Figure 2).
EXPRESSION
MOUSE
Transcripts for all mouse Nkrp1 genes have been detected in the
spleen, thymus, lymph nodes, and other hematopoietic tissues,
essentially wherever NK cells are found (53). Additionally, the
lung and intestine have shown expression of almost all Nkrp1 tran-
scripts (53). Nkrp1b/d is unique in showing expression within the
tongue and bladder (53). Within these tissues, Nkrp1a, Nkrp1b/d,
Nkrp1c, and Nkrp1f transcripts (Nkrp1g has not yet been
examined in detail) are present in NK cells, while Nkrp1c is also
found in NKT cells (53). Subsets of cells classified by various sort
markers as tissue DCs and macrophages have also been shown
to express Nkrp1b/d (53). Nkrp1f transcripts are also present in
BM DC/monocyte precursors and lymph node endothelial cells
(53), and expression has also been reported in DC/APC (72, 73).
Nkrp1b/d transcripts are also highly expressed in innate lym-
phoid cells (ILC), including ILC1, ILC2, ILC3, and LTi-like cells
(David Allan, manuscript submitted). They are also enriched in a
CD8αα+ subset of IEL; notably, these latter IEL also express greatly
enriched levels of transcripts for Nkrp1a, upregulated almost 30-
fold in CD8αα+ versus CD8αβ+ IEL (74). While Nkrp1c is found
in almost all NK and NKT cells, expression of Nkrp1b/d is found
at high levels in only a subset of NK cells (50–70%), but few NKT
cells (~10%) (40) (see also Peter Chen et al., Munir Rahim et al.,
manuscripts submitted).
Consistent with the transcript data, most NKR-P1 receptors are
expressed on mouse NK cells; however, few NKT cells express sur-
face NKR-P1 receptors, with the exception of NKR-P1C, which is
expressed at intermediate levels by NKT cells (40). Mouse NKR-
P1B/D is only detected at significant levels on a subset of NK
cells (~50–70%, depending on the strain), whereas the remain-
der expresses only low levels (18, 40). Strain-dependent NK1.1
expression is detectable on NK cells from a number of strains
(CE, B6, BTBR, KK, NZB, NZW, C57L, C58, Ma/My, ST, SJL, FVB,
and NIH-Swiss mice, but not 129, BALB/c, A/J, AKR, CBA, C3H,
DBA, LG, PL, or SM mice); however, expression of the particu-
lar NK1.1 antigen involved (NKR-P1B or NKR-P1C) seems to be
dictated by whether the majority of NK cells are NK1.1+ (NKR-
P1C), or whether the NK1.1 expression is variegated (NKR-P1B),
as determined by gating on DX5+ or NKp46+ NK cells (39, 40,
42). Surface expression of mouse NKR-P1G has not been docu-
mented yet, but it is predicted to be variegated, like NKR-P1B/D.
Interestingly, both activating and inhibitory NKR-P1 isoforms are
rapidly downregulated from the cell surface following ligation
by plate-bound antibody or cognate ligands (40). On the other
hand, surface NK1.1 (NKR-P1C) expression is induced on con-
ventional CD8+ T cells following viral infection and activation
by other stimuli (75–78). Expression of NK1.1 isoforms (NKR-
P1B>NKR-P1C) is also found on immature thymocytes, thymic
NK cells, fetal blood progenitors, subsets of mucosal T cells, and
some NKp46+ gut ILC (36, 79–86).
Expression of the mouse Clr ligand genes is variable and highly
regulated. Mouse Ocil (Clr-b) was reported to be expressed broadly
in most tissues (52, 53), but is also prevalent during bone devel-
opment and upregulated in response to osteotropic factors like
retinoic acid, 1,25-dihydroxyvitamin D3, parathyroid hormone,
IL-1α, and IL-11 (50). This regulation of Ocil appears to be
unique, as Ocilrp1 (Clr-d) and Ocilrp2 (Clr-g ) were not regu-
lated by these treatments, despite Ocilrp2 being co-localized in
the same tissues as Ocil (51). At the transcript level, Clr-a is
only expressed in the intestines, and even then only at low lev-
els (53). Clr-b is expressed in all nucleated hematopoietic cells,
some non-hematopoietic cells, and within most tissues, with the
exception of the brain, which appears to be devoid of Clr and
Nkrp1 transcript expression (20, 50, 53). In addition, Clr-b tran-
script expression is tightly regulated on healthy versus pathological
target cells. While expressed highly in normal cells, the transcripts
are lost following transformation (20), viral infection (45), and
genotoxic and cellular stress (87). Clr-c is expressed at low levels
in the tongue, spleen, thymus, ovaries, testes, and lymph node tis-
sues; Clr-d transcripts are uniquely present in the eye; and Clr-f
is expressed in the liver and very highly in the kidney and intes-
tine, specifically in intestinal epithelial cells and kidney tubular
epithelial cells (52, 53). Clr-g is expressed in the spleen, thymus,
and lymph node, particularly in intestinal epithelial cells, as well
as LAK cells (52, 53); notably, distinct Clr-g splice isoforms exist
(a.k.a., LCL-1a, -1b, -1c, -1d) that may have distinct expression
patterns (72, 73). Expression of the remaining family members
requires further investigation.
In terms of cell surface and protein expression, Clr-b has been
the most widely studied, as detected using 4A6 mAb (20, 87).
It appears to be a constitutive surface marker of healthy cells,
as nearly all nucleated hematopoietic cells express it, as do nor-
mal embryonic and adult skin fibroblasts (20, 87). In line with
this, Clr-b is frequently downregulated on pathological target
cells, including most hematopoietic tumor cell lines (20), virally
infected cells (e.g., MCMV, RCMV) (45), and cells undergoing
genotoxic or cellular stress (87). Thus, like MHC-I molecules, Clr-
b demonstrates a “missing-self” recognition pattern, expressed
by healthy cells but lost on target cells undergoing pathological
changes, making them more susceptible to NK cell effector func-
tion. Interestingly, the downregulation of Clr-b occurs at both the
transcript and protein levels, suggesting that transcriptional, as
well as post-transcriptional and post-translational mechanisms,
play important roles in regulating surface Clr-b expression, and
therefore regulating NK cell activity (45, 87). Notably, loss of
cell surface Clr-b expression on stressed cells is abrogated by
inhibitors of the ubiquitin–proteasome and endolysosomal path-
ways (e.g., MG132, lactacystin, chloroquine), many of which also
affect autophagy (87). Expression of the other mouse Clr family
members at the cell surface has been less documented due to a
paucity of specific mAb.
RAT
Where studied, expression in the rat system appears to be largely
similar to that of the mouse. Rat NKR-P1A transcripts are found in
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NK cells and NKT cells, and within tissues that contain these cells
(32). As in the mouse, the mAb that define rat NKR-P1 expression
(3.2.3, 10/78 mAb) identify all NK cells from most strains, where
they react with rat NKR-P1A, but these mAb also crossreact with
the NKR-P1B inhibitory receptor on certain strains (44, 88). In
PVG rats, two major subsets of NK cells can be phenotypically
and functionally classified based upon their variegated expres-
sion of Nkrp1b: NKR-P1B+ NK cells (largely CD94/NKG2A+ but
Ly49−); and Ly49s3+ NK cells (mostly NKR-P1B− Ly49+ and
responsive to MHC-I− targets) (43, 89). This pattern is sugges-
tive of subsets differentially regulated by MHC-I-dependent and
MHC-I-independent recognition mechanisms. In addition, fur-
ther characterization has revealed Nkrp1b to be highly expressed
by unique subset(s) of circulating and liver/gut-resident lym-
phocytes, some of which may include mature/activated NK cells
and/or ILC-like cells; these cells are enriched for CD8α, CD25,
CD93, CX3CR1, but depleted for CD62L, CD27, and CD11b
(90). Interestingly, Nkrp1g transcripts are exclusively expressed
in the Ly49s3+ subset, while Nkrp1f is expressed in both sub-
sets (22). This may be unique to the rat system, since mouse
Nkrp1(a, -c, -f, -g ) appear to be more equally expressed by
the variegated Nkrp1b+/− NK cell subsets (22). Little is known
regarding the surface expression of the rat NKR-P1F and NKR-
P1G receptors, although they are presumably expressed on the
surface of NK cells. Expression on ILC subsets remains to be
determined.
To date, little is known about the expression of the rat Clr
molecules, in part due to a paucity of specific mAb. As seen with
mouse Clr-b, rat Clr-11 (Clec2d11) is expressed broadly on ex vivo
hematopoietic cells (as assessed using R3A8 mAb) (45). More-
over, expression is rapidly lost in REF cells following infection
with RCMV-E (45). Whether or not this applies to other Clr fam-
ily members needs to be tested; notably, expression of another
Clr family member, Clec2d5, remained relatively unaffected or
increased. General expression profiles of some of the rat Clrs have
been inferred using qRT-PCR (69) or NKR-P1-bearing reporter
cells (BWN3G) mixed with various types of stimulator cells (59).
Ligand(s) for NKR-P1A/BF344 (most likely Clr-11) are expressed
by ex vivo splenocytes, peritoneal exudate cells, and to a lesser
degree on thymocytes, lymph node cells, and BM cells (59). This
overlaps the expression visualized using reporter cells bearing the
NKR-P1BPVG and NKR-P1BWAG alleles, which appear to respond
more strongly and uniformly to most or all of the above cell types
(especially BM cells) (45, 59). Similarly, NKR-P1F ligand(s) (most
likely some combination of Clr-2, -3, -4, -6, -7) are expressed on
peritoneal exudate cells, splenocytes, BM cells, thymocytes, and
lymph node cells (59). NKR-P1G ligands (likely Clr-2, -6, -7)
seem to be more restricted to peritoneal exudate cells, spleno-
cytes, and BM cells (59). However, it should be kept in mind
that an apparently restricted pattern may be partly due to non-
uniform expression or a differential reactivity of rodent reporter
cells expressing low or high-affinity receptors (e.g., NKR-P1BF344
versus NKR-P1BPVG/WAG) (45, 59). Interestingly, the RNK-16 rat
NK cell line appears to express ligands for all the rat NKR-P1 recep-
tors, while some tumor cells also express certain Clr ligands (22,
59). In one promoter study, binding sites for Sp1 family transcrip-
tion factors such as Sp1 and Sp7 were shown to have an important
role in the regulation of rat Ocil expression; however, the annotated
rat Ocil gene is Clec2d5 (Clr-5) not rat Clec2d11 (Clr-11) (58).
HUMAN
Human NKR-P1A is expressed on the majority of (but not all)
CD56bright CD16− and CD56dim CD16+ NK cells, as well as sub-
sets of CD4+ and CD8+ TCRαβ+ T cells, NKT cells, and TCRγδ+
T cells (48, 91, 92). It appears to be expressed on a higher propor-
tion of memory versus naïve T cells (46, 93). Induction of NKR-
P1A occurs in the fetal liver early in developmental ontogeny (46,
91), and it is one of the earliest markers of human NK cell develop-
ment (94–97). It is also expressed de novo on CD34− and CD34+
immature thymocytes, and is induced on thymocytes upon cul-
ture in rIL-2 (98). Surface NKR-P1A is upregulated on immature
and mature NK cells upon exposure to IL-12 (94, 99, 100). NKR-
P1A has also been reported to be a marker of all Th17 cell subsets
[where it is induced by RORC (101)], human ILC and LTi subsets
(102, 103), as well as a novel subset of FoxP3+ “Treg” found in
both healthy and arthritic humans that secrete pro-inflammatory
cytokines (104). CD4+ NKR-P1A+ T cells are capable of migra-
tion in transwell assays and transendothelial migration in vitro
(105). Acquisition of NKR-P1A has also been reported to be an
early event in monocyte differentiation and on DCs (106).
In contrast to mouse Clr-b and rat Clr-11, and perhaps
more akin to other rodent Clr, human LLT1 transcripts are only
expressed at low levels in NK cells, T cells, B cells, and osteoblasts,
but are undetectable in monocytes (65, 91, 107). In addition, LLT1
is expressed in some tumor lines, and its expression is greatly
increased by mitogen stimulation or activation of lymphocytes,
including LAK cells, NK cells, T cells, B cells, and DC (65, 91, 107).
Induction in osteoblasts has also been documented using IL-1α
and PGE2 (64). While freshly isolated B cells and DCs express
little LLT1 mRNA, transcript levels are augmented following infec-
tion with viral pathogens (e.g., influenza, HSV-1, EBV, HIV) or
TLR agonists (i.e., TLR-3, -4, -7, -8, -9), in particular CpG DNA
treatment (91, 107). Again unlike rodent Clr-b/Clr-11, LLT1 pro-
tein is not detected at the surface under naïve, resting conditions;
however, mirroring transcript expression, surface LLT1 is highly
upregulated upon activation with the stimuli noted above. Induc-
tion on B cells also occurs following IgM cross-linking or CD40
ligation. LLT1 expression is also inducible on T lymphocytes upon
stimulation via CD3 cross-linking, PMA, PHA, and IL-2 (61, 91,
107). On DC, the most potent inducers of LLT1 expression are
CpG DNA, polyI:C, LPS, TLR-7/8 agonists, and IFN-γ (107). LLT1
is also induced on NK cells upon activation, following incubation
with certain NK-sensitive target cells (91, 107). It remains to be
determined whether NKR-P1A:LLT1 interactions regulate NK and
T cell functions in cis, in addition to recognition of target cells in
trans (108, 109).
Expression of the other human CLEC2 ligands is more
restricted. As the names suggest, KACL (CLEC2A) is expressed
in keratinocytes, AICL (CLEC2B) is induced upon activation
of hematopoietic cells, CD69 (a.k.a., EA-1/AIM; CLEC2C) is
induced early after activation of T and NK lymphocytes and other
hematopoietic cells, BACL (CLEC2L) is expressed in brain tissue,
and the more distantly related DCAL (CLECL1) is expressed in
dendritic cells (23, 110).
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STRUCTURE
GENOMIC
In the mouse B6-strain reference genome, all of the Klrb1 genes
have six coding exons: exon-1 codes for the cytoplasmic domain,
exon-2 for the transmembrane domain, exon-3 for the stalk region,
and exons-4, -5, -6 for the extracellular lectin-like domain (21, 38).
This gene structure appears to be conserved for the Klrb1 genes in
the BALB/c and 129 strains (53), human KLRB1 (46), as well as the
Klrb1 genes in the rat BN-strain reference genome, with the excep-
tion of rat Nkrp1f (Klrb1c/f), which may have five to six exons,
depending upon reference genome build (7) (Table 1). Notably,
the human KLRF1 and KLRF2 genes also have a six-exon gene
structure (Figure 2; Table 1).
The Clec2 genes in the mouse and rat also have a similar
genomic structure. All the genes have five exons, with the fol-
lowing exceptions: mouse Clrg (Clec2i, six exons); mouse Clrd
(Clec2g, seven exons); mouse Clre (Clec2-ps1, three exons); mouse
Clrj (Clec2-ps3, two exons); rat Clr1 (Clec2d1, seven exons); rat Clr5
(Clec2d5, five to six exons); rat Clr7 (Clec2d7, six exons); rat Clr8
(Clec2d8p, four exons); and rat Clr9 (Clec2d9, six exons) (Table 2).
The human CLEC2D gene that encodes LLT1 (a.k.a., CLEC2D2)
also has five exons, as does the upstream CLEC2D1p pseudogene
(7). The human CLEC2A and CLEC2B genes also possess a five-
exon gene structure, and the same is true for the CLEC2C gene that
encodes CD69 (23, 110). The recently described CLEC2L (BACL)
Table 1 | Structure of the rodent and human Nkrp1-related genes
(Nkrp1/Klrb1; KLRB/F ).
Species Gene Exons Size
(kb)
Gene ID
(Entrez)
(Ref)
Mousea Nkrp1a (Klrb1a); MGI107540 6 13.7 17057
Nkrp1b (Klrb1b/d ); MGI107539 6 12.6 80782
Nkrp1c (Klrb1c); MGI107538 6 10.2 17059
Nkrp1e (Klrb1-ps1);
MGI3624540
6 12.9 724020
Nkrp1f (Klrb1f ); MGI2442965 6 11.5 232408
Nkrp1g (Klrb1/1g); MGI96877 6 16.5 100043861
Rata Nkrp1a (Klrb1a); RGD1586149 6 16.7 362443
Nkrp1b (Klrb1b); RGD1583688 6 12.4 678513
Nkrp1f (Klrb1c/f );
RGD1587571/1583336b
5–6b 4.1–11.6b 689809;
683758b
Nkrp1g (Klrb1/1d/1g);
RGD1587563
6 18.7 689817
Humana KLRB1 (NKR-P1A/CD161);
HGNC6373
6 12.6 3820
KLRF1 (NKp80); HGNC13342 6 17.5 51348
KLRF2 (NKp65); HGNC37646 6 14.3 100431172
aN.B., based upon the following genome builds: mouse B6-strain reference
sequence, December 2011, GRCm38/mm10; rat BN-strain reference sequence,
November 2004, Baylor 3.4/rn4; human genome reference sequence, February
2009, GRCh37/hg19.
bAmbiguity exists: rat genome build, March 2012, RGSC 5.0/rn5.
gene, which is not linked to the NKC, also possesses five exons, but
the less related CLECL1 (DCAL) gene linked to the NKC only has
four exons (Figure 2; Table 2).
The promoter regions of the rodent Nkrp1 and Clec2 genes
remain poorly characterized. There were early attempts to ana-
lyze the upstream regions of the mouse Nkrp1 genes in different
strains (49, 111). The proximal promoters appear to be TATA-
less, relying on initiator (Inr) and downstream promoter elements
(DPE) (111). The mouse Nkrp1 genes also appear to possess a
three-promoter organization similar to that seen for the mouse
Ly49 genes (112). Several predicted transcription factor-binding
sites in the distal and proximal promoter regions are speculated to
be important in regulating Nkrp1 expression, including consensus
Ets-1, Ikaros, GATA, TCF-1, Sp1, NFAT, and Oct-1 sites (111). In
addition, a number of upstream regulatory elements have been
Table 2 | Structure of the rodent and human C-type lectin-related
genes (Clr/Clec2 ; CLEC2 ).
Species Gene Exons Size
(kb)
Gene ID
(Entrez)
(Ref)
Mouse Clra (Clec2e); MGI3028921 5 9.0 232409
Clrb (Clec2d ); MGI2135589 5 5.9 93694
Clrc (Clec2f ); MGI3522133 5 6.4 435921
Clrd (Clec2g); MGI1918059 7 50.3 70809
Clre (Clec2-ps1) 3 13 (53)
Clrf (Clec2h); MGI2136934 5 14.9 94071
Clrg (Clec2i ); MGI2136650 6 9.2 93675
Clrh (Clec2j ); MGI3647940 5–6b 4.6–9b 677440 (53)
Clri (Clec2-ps2) 5 29 (53)
Clrj (Clec2-ps3) 2 1 (53)
Rat Clr1 (Clec2d1); RGD1564464 7 14.7 500331
Clr2 (Clec2d2); RGD1562831 5 8.1 362445
Clr3 (Clec2d3); RGD1588731 5 9.1 689757
Clr4 (Clec2d4); RGD1588718 5 17.4 689770
Clr5 (Clec2d5a); RGD620070 5–6b 10.0 113937
Clr6 (Clec2d6a); RGD1588698 5 7.3 689790
Clr7 (Clec2d7 ); RGD1587580 6 33.7 689800
Clr8 (Clec2d8p) 4 9 (7)
Clr9 (Clec2d9a); RGD1306865 6 106.1 312745
Clr10 (Clec2d10a); RGD1587527 5 5.3 689853
Clr11 (Clec2d11a); RGD1563148 5 8.6 362447
Human CLEC2A (KACL); HGNC24191 5 19.1 387836
CLEC2B (AICL); HGNC2053 5 17.5 9976
CLEC2C (CD69); HGNC1694 5 8.4 969
CLEC2D1p (LOC374443) 5 41.1 374443
CLEC2D2 (LLT1); HGNC14351 5 29.8 29121
CLEC2L (BACL); HGNC21969 5 21.1 154790
CLECL1 (DCAL); HGNC24462 5 17.4 160365
aAlternate names: rat Clec2d5 (Ocil; Clec2d); rat Clec2d6 (Clec2dl1); rat Clec2d9
(Clec2h); rat Clec2d10 (Clec2e); rat Clec2d11 (Clec2g). Based upon genome builds
outlined inTable 1.
bAmbiguities exist.
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mapped, including transcriptional start sites (TSS), alternative
exons, and a distal DNase hypersensitive site that may function
as an enhancer element. Luciferase-based reporter assays have
demonstrated that a 600-bp core promoter drives expression in
both T/NK lineage cells, while a 9.76-kb upstream region enhances
expression in NK-like cells but represses expression in pre-T cells,
suggesting lineage-specific regulation (111). Northern blot analy-
sis has revealed differential expression of Nkrp1a-c transcripts in
select strains, but culture of LAK cells in IL-2 could induce Nkrp1
expression where low (49).
In the mouse Clr system, Ocil/Clrb and Ocilrp2/Clrg have been
reported to possess an inverted TATA box upstream of their TSS,
while Ocilrp1/Clrd has a more traditional TATA box (51). Both
Ocilrp1/Clrd and Ocilrp2/Clrg have been reported to generate
alternative splice variants (51), and an independent characteri-
zation of LCL-1 (Ocilrp2/Clrg ) transcripts suggests that up to four
different splice variants exist (a–d) (72, 73). The human OCIL
(CLEC2D/LLT1) gene lacks an inverted TATA sequence, instead
containing a GAATCA sequence upstream of the TSS (64). The
human CLEC2D gene has also been reported to generate several
alternative splice variants (other than LLT1), some of which may be
functional (e.g., some code for proteins retained in the ER as het-
erodimers with LLT1, while others lack a transmembrane domain)
(65) (Oscar Aguilar, see GenBank KF958454-9, KF971856-9). As
mentioned above,Sp1 transcription factor-binding sites (Sp1,Sp7)
were shown to regulate expression of the rat Ocil gene (Clec2d5;
Clr-5) (58).
PROTEIN
The NKR-P1 and Clr proteins belong to group-V of the 14 C-type
lectin superfamily groups (7, 113). C-type lectins are a class of
glycoprotein characterized by their Ca2+ dependence, conserved
disulfide-linked cysteine residues, and functional carbohydrate
recognition domains (113). The NKR-P1 and Clr proteins are des-
ignated as “lectin-like” because they primarily bind other proteins,
and they possess somewhat atypical conservation of their cys-
teine residues, such that they may have lost the residues and loop
structures required to coordinate divalent calcium ions, and thus
may lack high-affinity Ca2+-dependent binding to carbohydrates.
For example, the mouse Clr and human LLT1 are all missing the
C5 residue in their lectin-like domain, and the C4 residue is also
absent from mouse Clr-b and Clr-g (52). The implications of these
changes require further investigation. However, it should be noted
that the NKR-P1 receptors were first reported to possess func-
tional carbohydrate recognition domains (54, 55). In addition,
the human LLT1/OCIL and mouse Clr-b/Ocil proteins have been
reported to bind high-molecular weight carbohydrates (includ-
ing sulfated forms) in a Ca2+-independent manner, blockable
using soluble carbohydrates (including heparin and chondroitin
sulfate) (64).
Initial work on the structure of the mouse NKR-P1 proteins
demonstrated that they likely exist as disulfide-linked homod-
imers. For example, NKR-P1D (NKR-P1BB6) is ~90 kDa under
non-reducing conditions, but ~47 kDa under reducing conditions,
when assessed using 2D12 mAb (18). The Clr proteins also likely
exist as homodimers, but heterodimers between different Clr have
also been speculated to exist (18). Crystal structures for the mouse
NKR-P1 proteins are just beginning to be published and assessed.
Although early co-crystal structures were first reported in 2003
for the mouse NKR-P1F:Clr-g and NKR-P1D:Clr-b proteins (the
latter reported under conditions requiring mutagenesis of certain
residues), these have not been published (18). Published work
suggests that mouse NKR-P1AB6 and NKR-P1CB6 have a similar
structure, with slight differences explainable by their amino acid
sequences (e.g., NKR-P1AB6 has a higher Y residue content than
NKR-P1CB6) (114). Mouse NKR-P1CB6 also has a better-defined
conformation of disulfide bridges than NKR-P1AB6, suggesting
that NKR-P1C is more rigid and stable; indeed, this is supported
in the literature regarding their individual stable expression at the
cell surface on NK cells (40). However, it should be noted that
the NKR-P1CBALB receptor lacks a potentially crucial conserved
C4 residue (position C122S) that may have implications for its
expression and function, in addition to its lack of NK1.1 reactivity
due to a S191T substitution (which is also found in the functional
NKR-P1BBALB receptor) (39, 115).
Rat NKR-P1A and NKR-P1B protein structures have also been
compared. Interestingly, rat NKR-P1A is more similar to mouse
NKR-P1A/C than to rat NKR-P1B (114). The rat NKR-P1B pro-
tein has more α-helical content (including an additional α-helix)
than rat NKR-P1A. The human NKR-P1A protein has been mod-
eled on these rodent NKR-P1 structures, where it more closely
resembles NKR-P1B than other isoforms, in that it is predicted to
retain an additional α-helix (114).
In general, all of the NKR-P1 proteins seem to possess a fold
similar to other C-type lectin-like domains, including at least two
α-helices and two anti-parallel β-sheets. They have a β-core com-
posed of long anti-parallel β-strands that form a central pillar,
flanked at one end by short β-strands and at the other end by
a β-sheet (114). This core is surrounded by α-helices (two to
three, depending on the isoform). All appear to have three disul-
fide bonds, except mouse NKR-P1CBALB, which has only two
(114). Comparison of all known NKR-P1 ectodomains revealed
the highest conservation in the β-core, less conservation in the
loop regions, with the longest loop suggested to play a role in lig-
and specificity (114). A mouse NKR-P1A crystal structure reported
recently suggests that a claw-like structure may be important for
ligand interaction (116).
A recent biochemical study of the human NKR-P1A:LLT1 pro-
teins have shown that they interact with a K d ~ 50µM (117).
Reciprocal mutagenesis of the proteins also provided a par-
tially validated structural model of the interaction, supporting a
dimeric interaction with several important contact residues. Even
more recent co-crystal structures of the high-affinity (K d ~ 2 nM)
human NKp65:KACL interaction have suggested a conserved
docking topology for the interaction of genetically linked C-
type lectin-like receptor–ligand pairs in the NKC (118). Here,
two NKp65 receptor monomers, with limited dimeric interface
between them, contact a single dimeric KACL ligand bivalently at
two distinct but symmetrical sites in a butterfly-shaped complex.
A similarity in this study was noted to the compact Ly49C dimer
interacting independently with two monomeric H-2Kb MHC-I
ligands (119). Whether or not this applies to other NKC-encoded
receptor–ligand pairs remains to be elucidated, but the remain-
ing genetically linked receptor–ligand interactions have all been
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shown to interact with much lower affinities (micromolar versus
nanomolar) (118).
Much less is known about the structure of the rodent Clr
or human LLT1 proteins. Human LLT1 has been modeled on a
CD69 structural backbone (65), and models have also been pro-
posed based upon mutagenesis studies (117), as well as the human
NKp65:KACL crystal structure (118). Recently, the structure and
biophysical properties of mouse Clr-g were determined by express-
ing soluble portions of the extracellular lectin-like domain (120).
In this structure, Clr-g exists as a monomer or dimer, depend-
ing on the size of the ectodomain used. In terms of secondary
structure, it has 2 α-helices, 2 anti-parallel β-sheets composed of
3 β-strands each, and 2 disulfide bonds, with a dimeric interface
involving 10 hydrogen bonds. Mouse Clr-g has mostly positive
electrostatic potential, while its cognate receptor, NKR-P1F, has
negative potential, suggesting electrostatic potential may be a dri-
ving force in their contact (120). Notably, models of the other Clr,
and other C-type lectin-like proteins, are predicted to possess dis-
tinct surface electrostatic potential in this work. Mouse Clr-g also
shares almost ~47% sequence identity with human KACL, and
predictive models of most of the human and mouse NKR-P1:Clr
receptor–ligand interactions have been outlined based upon the
human NKp65:KACL interaction (118).
FUNCTION
SIGNALING
Signaling via NK cell receptors is hypothesized to deliver either
an activating signal or to exert inhibitory effects on downstream
signaling cascades, and the NKR-P1 family is no exception to this
notion of paired or balanced recognition systems. Early experi-
ments demonstrated that Syk acts as a common signaling element
important for both FcR-initiated and natural cytotoxicity in NK
cells (121). However, additional pathways involving Src-family and
PI3K kinases are also involved in triggering natural cytotoxicity
(122–124).
In this light, it was shown that the mouse NKR-P1C recep-
tor activates both redirected cytotoxicity and IFN-γ production
in NK and NKT cells, and that association with the FcRγ adaptor
protein was crucial for these functions (28, 125). Furthermore,
while FcRγ homodimers were shown to be required for both
optimal NKR-P1C expression and signaling in both NK cells and
NKT cells (125), FcRγ/CD3ζ heterodimers may be sufficient for
residual NKR-P1C cell surface expression, in contrast to CD16
expression, which is dependent upon FcRγ homodimers and
is negatively regulated by CD3ζ (via FcRγ/CD3ζ heterodimers)
(126). In addition, the rat NKR-P1A receptor was shown to
induce Ca2+ flux, phosphatidylinositol turnover, PLA2 activation,
arachidonic acid release, heterotrimeric G-protein activation, redi-
rected cytotoxicity, and granule exocytosis by rat NK cells and the
RNK-16 cell line (127–129). Subsequent analysis of a number
of NKR-P1 protein sequences revealed the presence of poten-
tial PLC-γ1/2 motifs (YxxL), SH3-binding proline-rich domains,
Lck-recruitment motifs (CxCPR/H), and variably present con-
sensus ITIM motifs (ΦxYxxΦ) in the rodent but not human
NKR-P1 receptors (68). The activating rodent NKR-P1 recep-
tors were later shown to contain a conserved positively charged
amino acid residue (R) in their transmembrane domain, likely for
FcRγ adaptor association (based upon a distinct transmembrane
R amino acid position versus K for DAP12-associated receptors),
while the inhibitory rodent NKR-P1 receptors contain consensus
ITIM motifs (36, 68, 130).
Notably, the rodent NKR-P1 CxCPR/H motifs, similar to those
found in the CD4 and CD8 T cell co-receptors,were shown to func-
tionally recruit Lck by immunoprecipitation, yeast two-hybrid
analysis, and functional mutagenesis (131, 132). In addition, Lck
was also shown to be necessary for efficient NKR-P1C-mediated
redirected lysis, as cytotoxicity was diminished in BM-derived LAK
cells from Lck−/−mice (whereas splenic LAK cells may use another
Src-family member to compensate) (132). The ITIM motif in the
mouse NKR-P1B receptor was also shown to recruit the SHP-1
phosphatase upon pervanadate stimulation (and to a lesser extent
SHP-2) (36, 132). A consensus ITIM motif (133) is also present
in the mouse and rat NKR-P1G receptors, which are presumably
inhibitory; however, mouse NKR-P1G lacks the consensus Lck-
recruitment motif (21). The functional consequences of the loss
of the di-cysteine motif remain unknown, but may suggest a more
direct inhibitory receptor function versus a co-inhibitory receptor
function, if the CD4/8 T cell co-receptors provide any reference.
The mouse and rat NKR-P1F receptors may either be stimulatory,
co-stimulatory, or function as co-receptors in terms of signaling
(40), as they retain a charged transmembrane residue, yet mouse
NKR-P1F lacks the conserved YxxL motif, instead containing a Y
residue in a different position and context (21).
Like the rat NKR-P1A receptor (127), the mouse NKR-P1C
receptor (NK1.1 in B6 mice) has also been shown to signal IFN-γ
production in part via PI3K (p110γ> δ) activity (134), suggestive
of some co-stimulatory function, akin to NKG2D isoforms (135–
138). Given the specific expression of NKR-P1C on NKT cells
[but not other mouse NKR-P1 receptors (40)], its ability to recruit
Lck (akin to a T cell co-receptor), and its partial signaling via the
PI3K pathway (similar to CD28, NKG2D), it could serve as a co-
receptor or costimulatory receptor (signal 2) for TCR activation
(signal 1) on NKT cells in their recognition of CD1d-restricted
ligands. Since the mouse NKR-P1C ligand(s) remain unknown,
it is possible that endogenous or foreign glycolipids (and/or gly-
coproteins) could be recognized simultaneously by the NKT cell
TCR and this lectin-like receptor to facilitate dual recognition
(co-receptor or accessory function) and/or co-stimulation. Unlike
conventional MHC-restricted CD4+ and CD8+ T cells, NKT cells
are not yet known to express a co-receptor for CD1, although
they are tightly regulated by SAP/SLAM family interactions (13,
14). On the other hand, conventional NK cells express most NKR-
P1 receptor isoforms [whereas NKT cells more uniquely express
NKR-P1C (40)], and CD1d over-expression on target cells has
been reported to inhibit NK cell function via an as yet unidentified
receptor (139, 140).
Interestingly, the cytoplasmic tail of the human NKR-
P1A receptor contains neither a strong consensus ITIM motif
(ΦxYxxΦ) (133), nor an intact Lck-binding motif (CxCPR/H)
(68). Nonetheless, the human NKR-P1A cytoplasmic tail does con-
tain a tyrosine residue in an atypical motif (AxYxxL) that may
function as a weak ITIM (48, 68), and the receptor has been
shown by immunoprecipitation and Western blotting to form
large complexes containing the Src-family kinases, Lck, Fyn, and
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Lyn in Brij-58-solubilized NK cells (141). However, association
with SHP-1 has not been demonstrated (47, 48), and Lck associa-
tion was not observed in CD161+ NKT cells (142). The receptor
has been shown by yeast two-hybrid and co-immunoprecipitation
studies to associate with acid sphingomyelinase (aSM) in primary
human cell lines and NK cells (143). Ligation using CD161 mAb
results in association of CD161 with aSM in detergent-resistant
membranes, activation of aSM activity, production of ceramide,
PI3K-dependent activation of the Akt and ERK pathways, and pro-
liferation (143). Ligation of human NKR-P1A on thymocytes has
been reported to inhibit cytotoxicity but enhance proliferation
(98), expression on T cells enhances transendothelial migration
(105), and ligation on macrophages and DC fluxes intracellular
calcium and leads to IL-1α and IL-12 production (106). More
recently, human NKR-P1A has also been shown to be expressed
specifically by Th17 cells (101, 144), MR1-restricted MAIT cells
(145), and a unique “Treg” subset (104), where its function(s) are
still being evaluated (92).
AUTOIMMUNITY AND DISEASE ASSOCIATION
Human NKR-P1A was shown to be preferentially expressed on γδ
T cells expressing the Vδ2 chain (93). Interestingly, the proportion
of γδ T cells and IL-17+ T cells expressing NKR-P1A is higher
in MS patients than in healthy donors (93, 146). Upregulation of
human NKR-P1A on γδ T cells also occurs following exposure to
IL-12, as it does for NK cells, but only for the Vδ2+ population,
because Vδ1+ cells express lower levels of the IL-12Rβ2 subunit
(93). These NKR-P1A+Vδ2+ T cells also undergo transendothe-
lial migration in an NKR-P1A-dependent manner in vitro. Since
MS patients have more of these T cells, it has been proposed
that they use NKR-P1A to migrate to local lymph nodes, recir-
culate, and extravasate into the brain, leading to exacerbated MS
symptoms (93).
NKR-P1A+ T cells can also be detected in inflammatory infil-
trates in patients suffering from psoriasis (144) and Crohn’s disease
(147), with 20-fold more NKR-P1A+CD4+ T cells present in
patients with Crohn’s disease than healthy patients (147). Whether
this is due to upregulation of NKR-P1A on reactive T cells, or
exacerbated production or expansion of pre-existing NKR-P1A+
Th17 cells, requires further investigation (92). Importantly, how-
ever, an inflammatory bowel disease (IBD) susceptibility SNP in
the human LLT1/OCIL (CLEC2D) gene was recently found to be
associated with Crohn’s disease, but not ulcerative colitis (148).
Interestingly, an N19K substitution in the human LLT1/OCIL
(CLEC2D) gene has been found to be associated with reduced
bone mineral density in postmenopausal women (149). Genome-
wide association studies should reveal new interactions between
this receptor–ligand system and human disease.
VIRAL INFECTION
Viral evasion of host innate and adaptive immunity is a well-
documented evolutionary occurrence. In 2001, a spliced C-type
lectin-like ORF was identified in the RCMV-E genome (56). The
gene product was designated RCTL, and it was later shown to
closely resemble the coding sequence of an endogenous rat Clec2d-
like sequence, Clec2d11, a predicted functional homolog of mouse
Clr-b (Clec2d) (45). Indeed, an mAb specific for the RCTL protein
(R3A8 mAb) was also shown to crossreact with the host rat Clr-
11 (Clec2d11) protein. Expression of rctl was detected as early as
3 h post-infection (characterizing it as an early gene), while expres-
sion of host rat Clec2d11 was reciprocally lost from the cell surface,
replaced by RCTL (although heterodimers of host Clec2d11 and
RCTL may exist). BWZ.36 reporter cells expressing a CD3ζ/RCTL
fusion receptor responded strongly to 293T transfectants express-
ing the rat NKR-P1B receptor (indeed, only the NKR-P1BWAG
allele), suggesting a direct interaction between RCTL and the
inhibitory NK cell receptor. RCTL expression on infected cells
moderately inhibited WAG-strain LAK cell activity, an effect that
was abrogated with either R3A8 mAb blockade or infection using
an RCMV ∆RCTL-mutant virus (45). The ∆RCTL-mutant virus
exhibited lower splenic and liver titers in vivo, but only in rat
strains where the RCTL protein interacted strongly with the NKR-
P1B allele. Notably, weak recognition of RCTL was also shown by
the activating rat NKR-P1A receptor, suggesting that the host and
pathogen were evolving and counter-evolving this innate recog-
nition mechanism. Recently, downregulation of Clr-b has also
been shown to occur upon infection with poxviruses, including
vaccinia virus and ectromelia virus, where loss of the surface
protein was dependent upon active virus infection but not late
viral gene synthesis (150). It will be interesting to investigate the
roles of similar CMV-encoded genes with lectin-like homology
[e.g., r153 in RCMV-Maastricht (151)] in NK cell recognition,
as well as whether these CMV immunoevasins are capable of
heterodimerizing with host proteins (e.g., rat Clec2d1–11).
Induction of LLT1 surface expression has been shown to occur
upon infection with several viruses (e.g., EBV, HIV, influenza,
HSV) (91, 107). In addition, LLT1 induction by TLR agonists (e.g.,
TLR3, 4, 7, 8, 9) as well as other immune stimuli (such as TCR/BCR
cross-linking, mitogens, CD40, etc.) suggests that LLT1 interaction
with human NKR-P1A also regulates immune responses during
infection, particularly viral and bacterial infections (91, 107). In
this light, several lectin-like viral ORF (including those from vac-
cinia and other poxviruses) have been speculated to play roles in
the regulation of host immune responses, but none of these have
been evaluated to date (56).
T CELL CO-STIMULATION AND ADAPTIVE IMMUNITY
Few reports to date have examined the effects of the rodent NKR-
P1:Clr receptor–ligand system on the adaptive immune response.
Ligation of an Ocilrp2 splice isoform (LCL-1; Clr-g) expressed on
activated T cells by NKR-P1F on B cells and DC has been reported
in mice, leading to enhanced TCR/CD28-mediated T cell prolif-
eration and IL-2 production (73). However, the topology of this
interaction would not be predicted by the somewhat restricted
expression of NKR-P1F mainly within NK and T cells, with splice
variants of Clr-g being more broadly expressed (53). Thus, in light
of the recently identified“promiscuous”NKR-P1F:Clr-c, -d, -g and
NKR-P1G:Clr-d, -f, -g interactions (21), the reagents used in these
studies may possess multiple specificities (e.g., polyclonal anti-Clr-
g Ab could cross-react with other Clr, Ocilrp2–Ig fusion protein
could recognize both NKR-P1F/G, NKR-P1F tetramer could rec-
ognize Clr-c/d/g). Nonetheless, Clr-g was reported to be induced
more rapidly after CD3 cross-linking than other co-stimulatory
molecules (e.g., OX40, 4-1BB) (73). Also, the co-stimulatory effect
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of Clr-g was shown to require and synergize with CD28, while
OX40 and 4-1BB can act independently of CD28 (73). In a follow-
up study, silencing of Clr-g resulted in impaired T cell proliferation
and IL-2 production, due to an inability of the responding T cells to
phosphorylate Lck, reorganize the actin cytoskeleton, form TCR
caps, and transduce NFκB signals (72). These studies highlight
an important issue regarding the perceived roles of “receptor”
versus “ligand” (or vice versa) in NKR-P1:Clr interactions (51).
Notably, the mouse Clr-b protein has been suggested to possess
a TRAF2-interaction motif (130), supporting the possibility of
“reverse signaling” in regulation of NFκB signals by the Clr pro-
teins on target cells and APC, but the function of this motif has
not been investigated yet.
In the human system, CD161 on T cells may function as a
costimulatory receptor or accessory molecule for recognition of
CD1d (142). Ligation of CD161 on NKT cells did not directly
activate cytokine secretion (IFN-γ, IL-4), nor cause proliferation.
However, co-ligation of CD3 and CD161 could augment cytokine
production and proliferation, and this could be diminished using
soluble CD161 mAb. Similarly, while LLT1 inhibits cytotoxicity
and IFN-γ production via NKR-P1A on NK cells, it appears to
costimulate IFN-γ production by NKT cells (47, 107). Reciprocal
studies have suggested that LLT1 itself may signal on NK and NKT
cells to augment IFN-γ production via a Src-family–ERK signaling
pathway (61, 152).
RIBOZYME
A recent publication examined the presence of discontinuous
hammerhead ribozymes in mammalian genomes and identified
several such self-cleaving RNA motifs within the 3′-UTRs of
mouse Clec2e (Clr-a), mouse Clec2d (Clr-b), and rat Clec2d11
(Clr-b-like), along with others in the 3′-UTRs of predicted
Clec2-like genes in other species (153). Discontinuous ham-
merhead ribozymes differ from other ribozymes in that they
exist as two fragments (enzyme, substrate) in cis, separated
by an insertion of variable length sequence into the stem-1
loop, rather than being contiguous [reviewed in Ref. (154–
156)]. In the mouse Clec2d, mouse Clec2e, and rat Clec2d11
gene products, this insertion varies from ~250 to ~690 to ~790
nucleotides, respectively, and serves to separate the substrate
sequence (upstream) from the enzyme sequence (downstream)
(153). In addition, these ribozyme sequences were shown to be
catalytically active (with the mouse Clec2d ribozyme being more
active than the Clec2e ribozyme), reducing luciferase reporter
expression by ~80% due to autocatalytic reporter RNA degra-
dation (153). The net effect of these cleavage events would be
predicted to separate the mRNA 5′-cap and coding sequence
from the poly-A tail of the transcript, leading to altered RNA
stability. This suggests another possible level of regulation (post-
transcriptional) of the rodent Clec2d and Clec2e gene prod-
ucts, either enhancing mRNA turnover to provide more efficient
“missing-self” recognition, or providing a molecular switch to
turn on and off expression of the gene products during immune
responses.
Interestingly, other closely related Clec2 genes contain
substrate-like motifs in their 3′-UTRs (in the absence of corre-
sponding enzyme motifs), each with similar sequence identity to
the substrates in Clec2d and Clec2e (153). It would be interest-
ing to see whether these sequences can act in trans as substrates
for either the Clec2d or Clec2e enzyme components, akin to
micro-RNA-mediated regulation.
EVOLUTION
It is clear that the NKR-P1:Clr (Klrb:Clec2) systems, although
genetically linked, have undergone significant evolution between
species and between strains within a given species. It has been
proposed that the creation and deletion of Ly49 receptor genes
can occur by unequal crossing over during meiosis, generating
new inhibitory or stimulatory Ly49 by swapping the cytosolic
and transmembrane exons (which encode function) with the
ectodomain exons (which dictate specificity), even incorporating
pseudogene exons (17). The NKR-P1:Clr system is no exception
to this form of evolution, and the head-to-tail orientation of
some genes suggests how this may occur. Notably, the Nkrp1b
and Nkrp1c genes are arranged such that even a continuous tran-
script may be possible, splicing together the inhibitory region of
NKR-P1B and the NK1.1+ ectodomain of NKR-P1C, generat-
ing a novel inhibitory receptor that is NK1.1+ with new affinity
and/or specificity in certain mouse strains (Figure 2). This is also
possible for other Nkrp1 receptor and Clr ligand genes in mice,
rats, and perhaps humans. This arrangement would be ideal for
counter-evolving stimulatory receptors to directly recognize viral
decoys that inhibit NK cell function by co-opting self ligands, or
for modulating the specificity of self-specific inhibitory receptors
to counter–evade interaction with such decoys (45). In addition,
the promiscuity of the NKR-P1F/G receptors for overlapping lig-
ands may have evolved under selection pressure from viral evasion
strategies. Whether or not additional novel viral immunoevasins
exist that may target the NKR-P1:Clr systems is currently under
investigation.
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